Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a ...
The primary end point of the dose-expansion portion was safety of NBTXR3 at the recommended dosage, 1 which was established ...
FDA fast track designation for NG-350A aims to expedite its development for mismatch repair-proficient locally advanced ...
Trials should assess overall survival to evaluate potential harm, with crossover limited to avoid confounding treatment ...
Dr Colette Shen discusses the innovative Study 1100, exploring NBTXR3's safety and efficacy in treating recurrent head and ...
Xevinapant combined with CRT did not improve EFS in patients with unresected LA-SCCHN compared to placebo, showing a ...
Physician shortages are causing burnout, turnover, and patient access issues, with many considering early retirement or ...
T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...
With the 2025 European Society of Medical Oncology (ESMO) Congress kicking off on Friday, October 17, in Berlin, Germany, Targeted Oncology is bringing you background on the most exciting abstracts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback